Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 47, 2017 - Issue 12
295
Views
17
CrossRef citations to date
0
Altmetric
Pharmacogenetics

Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes

, , , , , , , , , & show all
Pages 1121-1129 | Received 06 Oct 2016, Accepted 09 Dec 2016, Published online: 03 Jan 2017

References

  • Bray MS, Boerwinkle E, Doris PA. (2001). High-throughput multiplex SNP genotyping with MALDI-TOF mass spectrometry: practice, problems and promise. Hum Mutat 17:296–304
  • Chen L, Qin S, Xie J, et al. (2008). Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics 9:691–702
  • Clendenen TV, Rendleman J, Ge W, et al. (2015). Genotyping of Single Nucleotide Polymorphisms in DNA Isolated from Serum Using Sequenom MassARRAY Technology. PLoS One 10:e0135943
  • Crettol S, Venetz JP, Fontana M, et al. (2008). CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit 30:689–99
  • Desta Z, Zhao X, Shin JG, Flockhart DA. (2002). Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913–58
  • De Pauw B, Walsh TJ, Donnelly JP, et al. (2008). Revised definitions of Invasive Fungal Diseases from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Disease Mycoses Study Group (EORTC/MSG) Consensus Group[J]. Clin Infect Dis 12:1813–21
  • Dolton MJ, Ray JE, Chen SC, et al. (2012). Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 56:4793–9
  • Dote S, Sawai M, Nozaki A, et al. (2016). A retrospective analysis of patient-specific factors on voriconazole clearance. J Pharm Health Care Sci. 19 2:10
  • Encalada Ventura MA, van Wanrooy MJ, Span LF, et al. (2016). Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations. Antimicrob Agents Chemother 60:2727–31
  • FDA Antiviral Drugs Advisory Committee.Briefing document for voriconazole (oral and intravenous formulations). (2001). Available at http://www.fda.gov/ohrms/dockets/AC/01/briefing/3792b2_01_Pfizer.pdf, 10-04
  • Guery BP, Arendrup MC, Auzinger G, et al. (2009). Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med 35:55–62
  • Gautier-Veyret E, Fonrose X, Tonini J, et al. (2015). Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels. Antimicrob Agents Chemother 59:2305–14
  • Hyland R, Jones BC, Smith DA. (2003). Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 31:540–7
  • Hamada Y, Seto Y, Yago K, et al. (2012). Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. J Infect Chemother 18:501–7
  • Hope WW, Castagnola E, Groll AH, et al. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 18 Suppl 7:38–52
  • Hoenigl M, Duettmann W, Raggam RB, et al. (2013). Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother 57:3262–7
  • He HR, Sun JY, Ren XD, et al. (2015). Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole. Eur J Clin Microbiol Infect Dis 34:811–19
  • Jeu L, Piacenti FJ, Lyakhovetskiy AG, et al. (2003). Voriconazole. Clin Ther 25:1321–81
  • Jin H, Wang T, Falcione BA, et al. (2016). Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother 71:1772–85
  • Kriengkauykiat J, Ito JI, Dadwal SS. (2011). Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol 3:175–91
  • Lamoureux F, Duflot T, Woillard JB, et al. (2016). Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. Int J Antimicrob Agents 47:124–31
  • Lee CR, Goldstein JA, Pieper JA. (2002). Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251–63
  • Lee S, Kim BH, Nam WS, et al. (2012). Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol 52:195–203
  • Lortholary O, Petrikkos G, Akova M, et al. (2012). ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect 18 Suppl 7:68–77
  • Li-Wan-Po A, Glrard T, Farndon P, et al. (2010). Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 69:222–30
  • Limper AH, Knox KS, Sarosi GA, et al. (2011). An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 183:96–128
  • Mizutani T. (2003). PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 35:99–106
  • Morrell M, Fraser VJ, Kollef MH. (2005). Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49:3640–5
  • Murayama N, Imai N, Nakane T, et al. (2007). Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti fungal agent, in human liver microsomes. Biochem Pharmacol 15 73:2020–6
  • Miyakis S, van Hal SJ, Ray J, et al. (2010). Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 16:927–33
  • Purkins L, Wood N, Ghahramani P, et al. (2002). Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 46:2546–53
  • Pfaller MA, Diekema DJ. (2004). Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 42:4419–31
  • Pascual A, Calandra T, Bolay S, et al. (2008). Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 15 46:201–11
  • Pascual A, Csajka C, Buclin T, et al. (2012). Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 55:381–90
  • Shi YY, He L. (2005). Shesis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15:97–8
  • Thomas RK, Baker AC, Debiasi RM, et al. (2007). High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347–51
  • Trembizki E, Smith H, Lahra MM, et al. (2014). High-throughput informative single nucleotide polymorphism-based typing of Neisseria gonorrhoeae using the Sequenom MassARRAY iPLEX platform. J Antimicrob Chemother 69:1526–32
  • Ullmann AJ, Akova M, Herbrecht R, et al. (2012). ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation(HCT). Clin Microbiol Infect 18 Suppl 7:53–67
  • Wang G, Lei HP, Li Z, et al. (2009). The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 65:281–5
  • Wang T, Chen S, Sun J, et al. (2014). Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. J Antimicrob Chemother 69:463–70
  • Weigel JD, Hunfeld NG, Koch BC, et al. (2015). Gain-of-function single nucleotide variants of the CYP2C19 gene (CYP2C19*17) can identify subtherapeutic voriconazole concentrations in critically ill patients: a case series. Intensive Care Med 41:2013–14
  • Weiss J, Ten Hoevel MM, Burhenne J, et al. (2009). CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 49:196–204
  • Zonios D, Yamazaki H, Murayama N, et al. (2014). Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis 15209:1941–8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.